540359 PARMAX

Parmax Pharma Share Price

 

 

Start SIP in PARMAX

Start SIP
Parmax Pharma live price: ₹31.18. It opened at ₹31 vs previous close ₹31; intraday high/low: ₹31/₹28. The 50 & 200 DMA stand at ₹30.45/₹34.03.

Parmax Pharma Performance

  • Today's Low
  • ₹28
  • Today's High
  • ₹31
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹55
  • Open Price₹31
  • Previous Close₹31
  • Volume349
  • 50 DMA₹30.45
  • 100 DMA₹31.96
  • 200 DMA₹34.03

Investment Returns

  • Over 1 Month -5.43%
  • Over 3 Month -7.37%
  • Over 6 Month + 2.23%
  • Over 1 Year -30.51%

Smart Investing Starts Here Start SIP with Parmax Pharma for Steady Growth!

Invest Now

Parmax Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -2.3
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 12
  • P/B Ratio
  • -1.9
  • Average True Range
  • 2.9
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.26
  • RSI
  • 55.22
  • MFI
  • 32.05

Parmax Pharma Financials

Parmax Pharma Technicals

EMA & SMA

Current Price
₹31.18
-0.25 (-0.8%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹28.83
  • 50 Day
  • ₹30.45
  • 100 Day
  • ₹31.96
  • 200 Day
  • ₹34.03

Resistance and Support

30.19 Pivot Speed
  • R3 35.79
  • R2 33.59
  • R1 32.39
  • S1 28.99
  • S2 26.79
  • S3 25.59

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Parmax Pharma has an operating revenue of Rs. 13.62 Cr. on a trailing 12-month basis. An annual revenue growth of 154% is outstanding, Pre-tax margin of -8% needs improvement, NULL From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Parmax Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-14 Quarterly Results
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-30 Audited Results
2025-02-14 Quarterly Results

Parmax Pharma F&O

Parmax Pharma Shareholding Pattern

30.8%
63.08%
6.12%

Parmax Pharma FAQs

Parmax Pharma share price is ₹31 As on 04 April, 2026 | 06:35

The Market Cap of Parmax Pharma is ₹11.7 Cr As on 04 April, 2026 | 06:35

The P/E ratio of Parmax Pharma is -2.3 As on 04 April, 2026 | 06:35

The PB ratio of Parmax Pharma is -1.9 As on 04 April, 2026 | 06:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23